The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer for Lemonaid Health, the virtual-care business it bought in 2021 for $400 million in cash and stock, people with knowledge of the efforts told BI. It’s not clear how formal the efforts have been. 23andMe didn’t respond to multiple requests for comment from BI. When 23andMe acquired Lemonaid, it said it wanted to provide personalized telemedicine care informed by its genetic-data collection.
Read the full article: 23andMe Has Been Quietly Exploring a Possible Sale of Its Telehealth Business, Lemonaid //
Source: https://www.msn.com/en-us/health/other/23andme-has-been-quietly-exploring-a-possible-sale-of-its-telehealth-business-lemonaid/ar-AA1xomek